Last reviewed · How we verify

DCCR — Competitive Intelligence Brief

DCCR (DCCR) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CDK8 inhibitor. Area: Oncology.

phase 3 CDK8 inhibitor CDK8 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

DCCR (DCCR) — Essentialis, Inc.. DCCR is a small molecule that inhibits the activity of the CDK8 protein.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DCCR TARGET DCCR Essentialis, Inc. phase 3 CDK8 inhibitor CDK8

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CDK8 inhibitor class)

  1. Essentialis, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DCCR — Competitive Intelligence Brief. https://druglandscape.com/ci/dccr. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: